Conference Coverage

ASH: Rituximab add-on therapy ‘new standard’ in BCP-ALL


 

AT ASH 2015

References

Allergic events – all but one from aspergillosis – were significantly more common in the control arm (2 events vs. 14 events; P = .002).

The Group for Research in Adult Acute Lymphoblastic Leukemia sponsored the study. Dr. Maury reported having no disclosures.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

What’s on tap at ASH 2015
MDedge Hematology and Oncology
Study: Pediatric cancer patients have high rate of germline mutations in predisposition genes
MDedge Hematology and Oncology
ASH: Donor CAR-T cells elicit responses in mixture of progressive B-cell cancers
MDedge Hematology and Oncology
ASH: Genes, induction response identify high risk childhood B-lymphoblastic leukemia patients with good outcomes
MDedge Hematology and Oncology
ASH: Pill bottles flag noncompliance in patients on ALL maintenance
MDedge Hematology and Oncology
ASH: Genes tag increased risk for avascular necrosis in ALL patients under age 10
MDedge Hematology and Oncology
EC grants conditional approval for blinatumomab
MDedge Hematology and Oncology
CHMP recommends pegaspargase for ALL
MDedge Hematology and Oncology
Donor CAR T cells treat aggressive ALL in infant
MDedge Hematology and Oncology
FDA approves generic imatinib
MDedge Hematology and Oncology